Clinical Study

Gladiator Uc: Etrasimod Versus Placebo For The Treatment Of Moderately Active Ulcerative Colitis

Posted Date: Sep 21, 2021

  • Investigator: Loren Brook
  • Specialties:
  • Type of Study: Drug

This study is to assess the efficacy of Etrasimod on clinical remission in subjects with moderately active ulcerative colitis (UC) after 12 weeks of treatment.


Age 18-80. Ability To Provide Written Informed Consent And To Be Compliant With The Schedule Of Protocol Assessments. Diagnosed With Ulcerative Colitis At Least 3 Months Prior To Screening.


Ulcerative Colitis, Uc

For More Information:

Missy Randolph

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.